Close Menu

NEW YORK – OpGen said Wednesday after the close of the market that its second quarter revenues grew 28 percent year over year as the company continues to await US Food and Drug Administration clearance for its antimicrobial resistance test.

For the three months ended June 30, the Gaithersburg, Maryland-based firm reported revenues of $1.0 million compared to $788,901 a year ago, on par with the average analyst estimate of $1.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.